[Treatment of central serous chorioretinopathy: MicroPulse photocoagulation versus bevacizumab].
OBJECTIVE
The aim of this study was to evaluate the treatment of central serous chorioretinopathy (CSC) with either subthreshold diode-laser MicroPulse (MP) or intravitreal bevacizumab (BCZ) using the Pro Re Nata (PRN) scheme.


METHODS
This comparative, controlled, prospective study over 10 months examined 52 eyes of 52 patients with either (a) treatment with MP at the active leakage site guided by fluorescein angiography (FA) (n=16 eyes), (b) intravitreal injection of 1.25 mg BCZ (n=10 eyes) or (c) passive observation (n=26 eyes). Outcome measures included changes in retinal pigment epithelium (RPE) leakage at FA, central macular thickness (CMT), best corrected visual acuity (BCVA) and 10° macular perimetry.


RESULTS
At the end of the study there was a 12.5 % persistent leakage in the MP group compared to 60 % in the BCZ group and 92 % in the control group. Mean CMT decreased by 94 µm in the MP, 38 µm in the BCZ and did not change in the control group. Mean BCVA improved by six ETDRS letters in the MP, decreased by one letter in the BCZ and by 2 letters in the control group. In the MP group mean perimetric deficit improved by 1.5 decibels and corrected lost variance by 2.6. In the BCZ it improved by 0.6 and by 0.5 in the control group. Retreatment was required in 7 out of 16 eyes of the SDM (43.75 %), and in 5 out of 10 eyes of the BCZ group (50 %).


CONCLUSIONS
MP photocoagulation was superior to intravitreal injections of 1.25 mg BCZ in the treatment of CSC which resulted in enhanced visual acuity and macular perimetry.
Studienzentrum Retina, Klinik für Glaskörper und Netzhautchirurgie, Zentrum der Augenheilkunde, Klinikum der Johann Wolfgang Goethe-Universität, Theodor Stern Kai 7 (Haus 7c), 60590, Frankfurt am Main, Deutschland. isbeger@stud.uni-frankfurt.de
I
I
Beger
M J
MJ
Koss
F
F
Koch
D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D056833:Central Serous Chorioretinopathy / Q000150:complications* / Q000175:diagnosis / Q000628:therapy*; D005260:Female; D006801:Humans; D008028:Light Coagulation / Q000379:methods*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D014786:Vision Disorders / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy*
D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab